var data={"title":"Aripiprazole (short-acting oral and injectable; and long-acting injectable [Abilify Maintena]): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Aripiprazole (short-acting oral and injectable; and long-acting injectable [Abilify Maintena]): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5669?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-drug-information\" class=\"drug drug_general\">see &quot;Aripiprazole (short-acting oral and injectable; and long-acting injectable [Abilify Maintena]): Drug information&quot;</a> and <a href=\"topic.htm?path=aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-patient-drug-information\" class=\"drug drug_patient\">see &quot;Aripiprazole (short-acting oral and injectable; and long-acting injectable [Abilify Maintena]): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50629640\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Atypical Antipsychotics Safety Review</span>\n      <span class=\"collapsible-date\">September 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Health Canada has reviewed the potential risk of sleep walking and sleep-related eating disorder with the use of atypical antipsychotics and concluded there is a link between these adverse reactions and the use of these medications. Health Canada has recommended to update the product safety information for all atypical antipsychotics to include these adverse reactions.</p>\n        <p style=\"text-indent:0em;\">Further information may be found at https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/atypical-antipsychotics-assessing-potential-risk-sleep-walking-sleep-related-eating-disorder.html.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708627\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Increased mortality in elderly patients with dementia-related psychosis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Aripiprazole is not approved for the treatment of patients with dementia-related psychosis.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Suicidality and antidepressant drugs:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening and for the emergence of suicidal thoughts and behaviors. The safety and efficacy of aripiprazole tablets with sensor have not been established in pediatric patients.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136801\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Abilify;</li>\n      <li>Abilify Discmelt [DSC];</li>\n      <li>Abilify Maintena</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9490633\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Abilify;</li>\n      <li>Abilify Maintena</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F999002\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Second Generation (Atypical) Antipsychotic </span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F999039\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-drug-information\" class=\"drug drug_general\">see &quot;Aripiprazole (short-acting oral and injectable; and long-acting injectable [Abilify Maintena]): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Oral solution may be substituted for the oral tablet on a mg-per-mg basis, up to 25 mg. Patients receiving 30 mg tablets should be given 25 mg oral solution. Orally disintegrating tablets (Abilify Discmelt) are bioequivalent to the immediate release tablets (Abilify). Immediate release and extended release parenteral products are <b>not</b> interchangeable.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Attention-deficit/hyperactivity disorder (ADHD):</b> Limited data available: Children &ge;8 years and Adolescents: Oral: Initial: 2.5 mg/day; may increase on a weekly basis by 2.5 mg/day increments as tolerated; maximum daily dose: 10 mg/day; dosing based on an open-label, pilot study (n=23, age: 8 to 12 years) which reported significant improvement in ADHD outcome scores without an impact on cognitive measures (positive or negative); mean final dose: 6.7 &plusmn; 2.4 mg/day (Findling 2008). Other aripiprazole published reports in pediatric and adolescent patients in which ADHD is a comorbid diagnosis within the study population exist; however, effectiveness in ADHD was not a reported primary outcome measure (Bastiaens 2009; Budman 2008; Findling 2009; Murphy 2009; Valicenti-McDermott 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Autism; treatment of associated irritiability (including aggression, deliberate self-injurious behavior, temper tantrums, and quickly changing moods):</b> Children and Adolescents 6 to 17 years: Oral: Initial: 2 mg daily for 7 days, followed by 5 mg daily; subsequent dose increases may be made in 5 mg increments every &ge;7 days, up to a maximum daily dose of 15 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bipolar I disorder (acute manic or mixed episodes):</b> Children and Adolescents 10 to 17 years: Oral: Initial: 2 mg daily for 2 days, followed by 5 mg daily for 2 days with a further increase to target dose of 10 mg daily; subsequent dose increases may be made in 5 mg increments, up to a maximum daily dose of 30 mg/<b>day</b>. <b>Note:</b> The safety of doses &gt;30 mg/day has not been evaluated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Conduct disorder (CD); aggression:</b> Limited data available: Children &ge;6 years and Adolescents: Oral: Initial: Patient weight &lt;25 kg: 1 mg/day; 25 to 50 kg: 2 mg/day; 51 to 70 kg: 5 mg/day; &gt;70 kg: 10 mg/day; may titrate after 2 weeks to clinical effectiveness; maximum daily dose: 15 mg/<b>day</b>. Dosing based on an open-label, prospective study (n=23; age: 6 to 17 years) which evaluated pharmacokinetics and effectiveness in patients with a primary diagnosis of CD (with or without comorbid ADHD); results showed improvement in CD symptom scores with only minor improvements in cognition (Findling 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) or Asperger Disorder; treatment of associated irritability (aggression, self-injury, tantrums):</b> Limited data available: Children &ge;4 years and Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Preschool age: Initial dose: 1.25 mg/day with titration every &ge;5 days in 1.25 mg/day increments as tolerated or clinically indicated (Masi 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prepubertal children: Initial dose: 1.25 to 2.5 mg/day with titration every 3 to 5 days in 1.25 to 2.5 mg/day increments as tolerated or clinically indicated; maximum daily dose: 15 mg/<b>day</b> (Masi 2009; Stigler 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: Initial dose: 2.5 to 5 mg/day with titration every 5 days in 2.5 to 5 mg/day increments as tolerated or clinically indicated; doses &gt;5 mg/day were divided twice daily; if sleep disorder was reported, the dose was given in morning and/or at lunchtime (Masi 2009); maximum daily dose: 15 mg/<b>day</b> (Stigler 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">An open-labeled, pilot study (n=25; mean age: 8.6 years; range: 5 to 17 years) reported an 88% response with a mean final dose of 7.8 mg/day (range: 2.5 to 15 mg/day) (Stigler 2009). A retrospective, noncontrolled, open-label study of 34 PDD patients (mean age: 10.2 years; range: 4 to 15 years) included 10 patients with autistic disorder and 24 patients with PDD-NOS reported a mean final dose: 8.1 &plusmn; 4.9 mg/day and an overall response rate of 32.4% (29.2% in patients with PDD-NOS) (Masi 2009). In a retrospective chart review of children and adolescents with developmental disability and a wide range of psychiatric disorders (n=32; age: 5 to 19 years), a mean starting dose of aripiprazole of 7.1 &plusmn; 0.32 mg/day and a mean maintenance dose of 10.55 &plusmn; 6.9 mg/day was used; a response rate of 56% was reported for the overall population. However, a study population subset analysis in patients with mental retardation (n=18) showed a lower response rate in patients with mental retardation with PDD-NOS (38%) than in patients with mental retardation without PDD-NOS (100%) (Valicenti-McDermott 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Schizophrenia:</b> Adolescents 13 to 17 years: Oral: Initial: 2 mg daily for 2 days, followed by 5 mg daily for 2 days with a further increase to target dose of 10 mg daily; subsequent dose increases may be made in 5 mg increments up to a maximum daily dose of 30 mg/<b>day</b>. <b>Note:</b> 30 mg/day was <b>not</b> found to be more effective than the 10 mg/day dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Tourette syndrome, tic disorders:</b> Children &ge;6 years and Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patient weight &lt;50 kg: Initial: 2 mg daily for 2 days, then increase to target dose of 5 mg/day; in patients not achieving optimal control, dose may be further titrated at weekly intervals up to 10 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patient weight &ge;50 kg: Initial: 2 mg daily for 2 days, then increase to 5 mg/day for 5 days, then increase to target dose of 10 mg/day on day 8 of therapy; in patients not achieving optimal control, dose may be further titrated at weekly intervals in 5 mg/day increments up to 20 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute agitation (schizophrenia/bipolar mania):</b> IM: Immediate release: 9.75 mg as a single dose (range: 5.25 to 15 mg; a lower dose of 5.25 mg IM may be considered when clinical factors warrant); may repeat at &ge;2-hour intervals to a maximum daily dose of 30 mg/day; <b>Note:</b> If ongoing therapy with aripiprazole is necessary, transition to oral therapy as soon as possible.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bipolar I disorder (acute manic or mixed episodes): </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Monotherapy: Initial: 15 mg once daily. May increase to 30 mg once daily if clinically indicated (maximum 30 mg/day); safety of doses &gt;30 mg/day has not been evaluated</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adjunct to lithium or valproic acid: Initial: 10 to 15 mg once daily. May increase to 30 mg once daily if clinically indicated (maximum: 30 mg/day); safety of doses &gt;30 mg/day has not been evaluated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Depression (adjunctive with antidepressants):</b> Oral: Initial: 2 to 5 mg/day (range: 2 to 15 mg/day); dosage adjustments of up to 5 mg/day may be made in intervals of &ge;1 week up to a maximum of 15 mg/day; <b>Note:</b> Dosing based on patients already receiving antidepressant therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Schizophrenia: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 10 to 15 mg once daily; may be increased to a maximum of 30 mg once daily (efficacy at dosages above 10 to 15 mg has not been shown to be increased). Dosage titration should not be more frequent than every 2 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM, extended release (Abilify Maintena): 400 mg once monthly (doses should be separated by &ge;26 days); <b>Note:</b> Tolerability should be established using oral aripiprazole prior to initiation of parenteral therapy. Continue oral aripiprazole (or other oral antipsychotic) for 14 days during initiation of parenteral therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Missed doses:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Second or third doses missed:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&gt;4 weeks but &lt;5 weeks since last dose: Administer next dose as soon as possible</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&gt;5 weeks since last dose: Administer oral aripiprazole for 14 days with next injection</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Fourth or subsequent doses missed:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&gt;4 weeks but &lt;6 weeks since last dose: Administer next dose as soon as possible</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&gt;6 weeks since last dose: Administer oral aripiprazole for 14 days with next injection</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Dosage adjustment for adverse effects:</i> Consider reducing dose to 300 mg once monthly</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Discontinuation</b>\n      <b> of therapy: </b>Children, Adolescents, and Adults: American Academy of Child and Adolescent Psychiatry (AACAP), American Psychiatric Association (APA), Canadian Psychiatric Association (CPA), National Institute for Health and Care Excellence (NICE), and World Federation of Societies of Biological Psychiatry (WFSBP) guidelines recommend gradually tapering antipsychotics to avoid withdrawal symptoms and minimize the risk of relapse (AACAP [McClellan 2007]; APA [Lehman 2004]; Cerovecki 2013; CPA 2005; NICE 2013; WFSBP [Hasan 2012]); risk for withdrawal symptoms may be highest with highly anticholinergic or dopaminergic antipsychotics (Cerovecki 2013). When stopping antipsychotic therapy in patients with schizophrenia, the CPA guidelines recommend a gradual taper over 6 to 24 months and the APA guidelines recommend reducing the dose by 10% each month (APA [Lehman 2004]; CPA 2005). Continuing antiparkinsonism agents for a brief period after discontinuation may prevent withdrawal symptoms (Cerovecki 2013). When switching antipsychotics, three strategies have been suggested: Cross titration (gradually discontinuing the first antipsychotic while gradually increasing the new antipsychotic), overlap and taper (maintaining the dose of the first antipsychotic while gradually increasing the new antipsychotic, then tapering the first antipsychotic), and abrupt change (abruptly discontinuing the first antipsychotic and either increasing the new antipsychotic gradually or starting it at a treatment dose). Evidence supporting ideal switch strategies and taper rates is limited and results are conflicting (Cerovecki 2013; Remington 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment with concurrent CYP450 inducer or inhibitor therapy:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Children, Adolescents, and Adults; IM (immediate release): Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CYP3A4 inducers (eg, carbamazepine, rifampin): Aripiprazole dose should be doubled over 1 to 2 weeks; dose should be subsequently reduced if concurrent inducer agent discontinued.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Strong CYP3A4 inhibitors (eg, ketoconazole): Aripiprazole dose should be reduced to 50% of the usual dose, and proportionally increased upon discontinuation of the inhibitor agent.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CYP2D6 inhibitors (eg, fluoxetine, paroxetine): Aripiprazole dose should be reduced to 50% of the usual dose, and proportionally increased upon discontinuation of the inhibitor agent. <b>Note:</b> When aripiprazole is administered as adjunctive therapy to patients with MDD, the dose should <b>not</b> be adjusted, follow usual dosing recommendations.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CYP3A4 and CYP2D6 inhibitors: Aripiprazole dose should be reduced to 25% of the usual dose. In patients receiving inhibitors of differing (eg, moderate 3A4/strong 2D6) or same (eg, moderate 3A4/moderate 2D6) potencies (excluding concurrent strong inhibitors), further dosage adjustments can be made to achieve the desired clinical response. In patients receiving strong CYP3A4 and 2D6 inhibitors, aripiprazole dose is proportionally increased upon discontinuation of one or both inhibitor agents.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM, extended release (Abilify Maintena): Adults: <b>Note:</b> Dosage adjustments are not recommended for concomitant use of CYP3A4 inhibitors, CYP2D6 inhibitors, or CYP3A4 inducers for &lt;14 days. In patients who had their aripiprazole dose adjusted for concomitant therapy, the aripiprazole dose may need to be increased if the CYP3A4 and/or CYP2D6 inhibitor is withdrawn.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CYP3A4 inducers: Avoid use; aripiprazole serum concentrations may fall below effective levels.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Strong CYP3A4 <b>or</b> CYP2D6 inhibitors:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Current aripiprazole dose of 300 mg once monthly: Reduce aripiprazole dose to 200 mg once monthly</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Current aripiprazole dose of 400 mg once monthly: Reduce aripiprazole dose to 300 mg once monthly</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Strong CYP3A4 inhibitors <b>and</b> CYPD2D6 inhibitors:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Current aripiprazole dose of 300 mg once monthly: Reduce aripiprazole dose to 160 mg once monthly</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Current aripiprazole dose of 400 mg once monthly: Reduce aripiprazole dose to 200 mg once monthly</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment based on CYP2D6 metabolizer status:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Children, Adolescents, and Adults: IM (Immediate release): Adults: Aripiprazole dose should be reduced to 50% of the usual dose in CYP2D6 poor metabolizers and to 25% of the usual dose in poor metabolizers receiving a concurrent strong CYP3A4 inhibitor; subsequently adjust dose for favorable clinical response.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM, extended release (Abilify Maintena): Adults: Reduce aripiprazole dose to 300 mg once monthly in CYP2D6 poor metabolizers; reduce dose to 200 mg once monthly in CYP2D6 poor metabolizers receiving a concurrent CYP3A4 inhibitor for &gt;14 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> No dosage adjustment required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> No dosage adjustment required.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136774\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Prefilled Syringe, Intramuscular: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Abilify Maintena: 300 mg (1 ea); 400 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intramuscular: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Abilify: 9.75 mg/1.3 mL (1.3 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Abilify: 1 mg/mL (150 mL [DSC]) [contains methylparaben, propylene glycol, propylparaben; orange cream flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg/mL (150 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted ER, Intramuscular: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Abilify Maintena: 300 mg (1 ea); 400 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Abilify: 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg [contains corn starch, fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Disintegrating, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Abilify Discmelt: 10 mg [DSC], 15 mg [DSC] [contains aspartame, fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg, 15 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136761\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26641004\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-drug-information\" class=\"drug drug_general\">see &quot;Aripiprazole (short-acting oral and injectable; and long-acting injectable [Abilify Maintena]): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Oral solution contains fructose 200 mg and sucrose 400 mg per mL.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49685671\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Abilify immediate-release injection (9.75 mg/1.3 mL) has been discontinued in the US for more than 1 year.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Abilify Mycite: FDA approved November 2017; availability anticipated in 2018. Information pertaining to this product within the monograph is pending revision. Abilify Mycite is a drug-device combination product comprised of aripiprazole tablets embedded with an Ingestible Event Marker (IEM) sensor intended to track drug ingestion. Consult the prescribing information for additional information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874282\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Abilify: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/ucm085804.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9+evs591MjKrfB30zg8bRlw3TqxcQ3MvJSiw1+13S5Mg==&amp;TOPIC_ID=13180\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm085804.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Abilify Maintena: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM342207.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9BK5et6GehFK9IioulPK5WJJMYPuztaHMaLkKHuMuvAQ==&amp;TOPIC_ID=13180\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM342207.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F999047\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral (all dosage forms): May be administered with or without food.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Orally-disintegrating tablet: Do not remove tablet from blister pack until ready to administer; do not push tablet through foil (tablet may become damaged); peel back foil to expose tablet; use dry hands to remove tablet and place immediately on tongue. Tablet dissolves rapidly in saliva and may be swallowed without liquid; if needed, tablet can be taken with liquid. Do not split tablet.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: For IM use only; do not administer SubQ or IV; <b>Note:</b> Immediate release and extended release parenteral products are <b>not</b> interchangeable.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release (Abilify): Inject slowly into deep muscle mass</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release (Abilify Maintena): Inject slowly into deltoid or gluteal muscle using the provided 1.5 inch (38 mm) needle for nonobese patients or the provided 2 inch (50 mm) needle for obese patients. Do not massage muscle after administration. Rotate injection sites between the two gluteal muscles. Administer monthly (doses should be separated by &ge;26 days).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136797\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, powder (extended release):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prefilled syringe: Store below 30&deg;C (86&deg;F). Do not freeze. Protect from light and store in original package.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vial for reconstitution: Store unused vials at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). If the suspension is not administered immediately after reconstitution, store at room temperature in the vial (do not store in a syringe).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, solution (immediate release): Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light. Retain in carton until time of use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral solution and tablets: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Use oral solution within 6 months after opening. Do not store in conditions where tablets are exposed to humid conditions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycite Patch: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); 15% to 93% relative humidity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F999003\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Acute and maintenance treatment of schizophrenia (FDA approved in ages &ge;13 years and adults); acute treatment of bipolar disorder (with acute manic or mixed episodes) (FDA approved in ages &ge;10 years and adults); adjunctive therapy (to lithium or valproate) for acute treatment of bipolar disorder (with acute manic or mixed episodes) (FDA approved in ages &ge;10 years and adults); treatment of irritability associated with autistic disorder (including symptoms of aggression, deliberate self-injurious behavior, temper tantrums, quickly changing moods) (FDA approved in ages 6 to 17 years); treatment of Tourette's disorder (FDA approved in ages 6 to 18 years); adjunctive treatment (to antidepressants) of major depressive disorder (FDA approved in adults). Has also been used in children and adolescents for treatment of ADHD, conduct disorders, and irritability associated with other pervasive developmental disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: Abilify:  Acute treatment of agitation associated with schizophrenia or bipolar disorder (manic or mixed) (FDA approved in adults) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: Abilify Maintena: Treatment of  schizophrenia (FDA approved in adults) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136828\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Abilify may be confused with Ambien</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">ARIPiprazole may be confused with proton pump inhibitors (dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole, RABEprazole)</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Antipsychotics are identified in the Beers Criteria as potentially inappropriate medications to be avoided in patients 65 years and older with dementia due to an increased risk of mortality, cerebrovascular accidents (stroke), and a greater rate of cognitive decline with use; avoid antipsychotics for behavioral problems associated with dementia or delirium unless alternative nonpharmacologic therapies have failed and patient may harm self or others. Use <i>may be appropriate</i> in geriatric patients with schizophrenia, bipolar disorder, or for short-term use as an antiemetic during chemotherapy. In addition, antipsychotics should be used with caution in older adults due to their potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">There are two formulations available for intramuscular administration: Abilify is an immediate release short-acting formulation and Abilify Maintena is an extended-release formulation. These products are <b>not</b> interchangeable.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136826\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Orthostatic hypotension, peripheral edema, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Agitation (more common in oral), akathisia (more common in adults), anxiety (more common in oral), ataxia, dizziness, drooling, drowsiness (more common in children and adolescents), dystonia, extrapyramidal reaction (more common in children and adolescents), fatigue (more common in children and adolescents), headache (more common in adults), hypersomnia, insomnia (less common in injection), irritability, lethargy, pain, restlessness, sedation (more common in children and adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Decreased HDL cholesterol (more common in adults), increased LDL cholesterol, increased serum cholesterol (more common in injection), increased serum glucose (more common in adults), increased serum triglycerides (more common in injection), weight gain (more common in children and adolescents), weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal distress, anorexia, constipation, decreased appetite, diarrhea, dyspepsia, gastric distress, increased appetite, nausea, sialorrhea, stomach discomfort, toothache, upper abdominal pain, vomiting (more common in oral), xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Dysmenorrhea, urinary incontinence</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Neutropenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Application site rash (Mycite patch), injection site reaction (injection; including erythema, induration, inflammation, hemorrhage, pruritus, swelling, rash), pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, back pain, dyskinesia, limb pain, muscle cramps, muscle rigidity, muscle spasm, musculoskeletal pain, myalgia, stiffness, tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Aspiration pneumonia, cough, dyspnea, epistaxis, nasal congestion, nasopharyngitis, pharyngolaryngeal pain, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abnormal bilirubin levels, abnormal gait, abnormal hepatic function tests, aggressive behavior, agranulocytosis, akinesia, alopecia, altered serum glucose, amenorrhea, anaphylaxis, angina pectoris, angioedema, anorgasmia, atrial fibrillation, atrial flutter, atrioventricular block, bradycardia, bradykinesia, bruxism, cardiac arrhythmia, catatonia, cerebrovascular accident, change in libido, chest discomfort, chest pain, choreoathetosis, cogwheel rigidity, decreased serum cholesterol, decreased serum triglycerides, delayed ejaculation, delirium, depression, diabetes mellitus, diabetic ketoacidosis, diplopia, disruption of body temperature regulation, drug-induced Parkinson disease, dysgeusia, dysphagia, dystonia (oromandibular), edema, elevated glycosylated hemoglobin, erectile dysfunction, esophagitis, extrasystoles, eyelid edema, facial edema, falling, gastroesophageal reflux disease, glycosuria, gynecomastia, heatstroke, hepatic failure, hepatitis, hepatotoxicity, hirsutism, homicidal ideation, hostility, hyperglycemia, hyperhidrosis, hyperinsulinism, hyperlipidemia, hypersensitivity reaction, hypertension, hypertonia, hypoglycemia, hypokalemia, hypokinesia, hyponatremia, hypothermia, hypotonia, impulse control disorder (including pathologic gambling and hypersexuality), increased blood urea nitrogen, increased creatinine clearance, increased creatine phosphokinase, increased gamma-glutamyl transferase, increased lactate dehydrogenase, increased liver enzymes, increased serum bilirubin, increased serum prolactin, inhibition of prolactin secretion, intentional injury, ischemic heart disease, jaundice, joint stiffness, laryngospasm, leukopenia, mastalgia, memory impairment, menstrual disease, mobility disorder, muscle twitching, myasthenia, myocardial infarction, myoclonus, neuroleptic malignant syndrome, nocturia, obesity, oculogyric crisis, oropharyngeal spasm, palpitations, pancreatitis, panic attack, photophobia, photopsia, pollakiuria, polydipsia, polyuria, presyncope, priapism, prolonged Q-T interval on ECG, pruritus, psychosis, rhabdomyolysis, seizure (including injection), skin photosensitivity, sleep apnea syndrome (obstructive) (Health Canada, August 16, 2016; Shirani 2011), sleep talking, somnambulism, speech disturbance, suicidal ideation, suicidal tendencies, supraventricular tachycardia, swollen tongue, syncope, tardive dyskinesia, thrombocytopenia, tics, tongue spasm, tonic-clonic seizures, torsades de pointes, transient ischemic attacks, trismus, uncontrolled diabetes mellitus, urinary retention, urticaria, venous thromboembolism, ventricular tachycardia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136781\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity (eg, anaphylaxis, pruritus, urticaria) to aripiprazole or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136764\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Major psychiatric warnings:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Suicidal thinking/behavior: <b>[US Boxed Warning]: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18 to 24 years of age) with major depressive disorder (MDD) and other psychiatric disorders;</b> consider risk prior to prescribing. Short-term studies did not show an increased risk in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years. Closely monitor patients for clinical worsening, suicidality, or unusual changes in behavior, particularly during the initial 1 to 2 months of therapy or during periods of dosage adjustments (increases or decreases); the patient's family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider. A medication guide concerning the use of antidepressants should be dispensed with each prescription. Aripiprazole is not FDA approved for adjunctive treatment of depression in children.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">-The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy. Patients should be screened for bipolar disorder prior to initiation of treatment of major depression.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their healthcare provider if any of these symptoms or worsening depression or psychosis occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse reactions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered cardiac conduction: May alter cardiac conduction; life-threatening arrhythmias have occurred with therapeutic doses of antipsychotics.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood dyscrasias: Leukopenia, neutropenia, and agranulocytosis (sometimes fatal) have been reported in clinical trials and postmarketing reports with antipsychotic use; presence of risk factors (eg, preexisting low WBC/ANC or history of drug-induced leuko-/neutropenia) should prompt periodic blood count assessment. Discontinue therapy at first signs of blood dyscrasias or if absolute neutrophil count &lt;1,000/mm<sup>3</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cerebrovascular effects: An increased incidence of cerebrovascular effects (eg, transient ischemic attack, stroke), including fatalities, has been reported in placebo-controlled trials of aripiprazole for the unapproved use in elderly patients with dementia-related psychosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dyslipidemia: Has been reported with atypical antipsychotics; risk profile may differ between agents. In clinical trials, lipid changes observed with aripiprazole monotherapy were similar to those observed with placebo.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Esophageal dysmotility/aspiration: Antipsychotic use has been associated with esophageal dysmotility and aspiration; use with caution in patients at risk for aspiration pneumonia (eg, Alzheimer dementia).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extrapyramidal symptoms (EPS): May cause extrapyramidal symptoms, including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia (risk of these reactions is generally much lower relative to typical/conventional antipsychotics; frequencies reported are similar to placebo). Risk of dystonia (and probably other EPS) may be greater with increased doses, use of conventional antipsychotics, males, and younger patients. Factors associated with greater vulnerability to tardive dyskinesia include older in age, female gender combined with postmenopausal status, Parkinson disease, pseudoparkinsonism symptoms, affective disorders (particularly major depressive disorder), concurrent medical diseases such as diabetes, previous brain damage, alcoholism, poor treatment response, and use of high doses of antipsychotics (APA [Lehman 2004]; Soares-Weiser 2007). Consider therapy discontinuation with signs/symptoms of tardive dyskinesia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Falls: May increase the risk for falls due to somnolence, orthostatic hypotension and motor or sensory instability. Complete fall risk assessments at baseline and periodically during treatment in patients with diseases or on medications that may also increase fall risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperglycemia: Atypical antipsychotics have been associated with development of hyperglycemia; in some cases, may be extreme and associated with ketoacidosis, hyperosmolar coma, or death. Use with caution in patients with diabetes or other disorders of glucose regulation; monitor for worsening of glucose control. Patients with risk factors for diabetes (eg, obesity or family history) should have a baseline fasting blood sugar (FBS) and periodic assessment of glucose regulation. Reports of hyperglycemia with aripiprazole therapy have been few and specific risk associated with this agent is not known.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Impulse control disorders: Has been associated with compulsive behaviors and/or loss of impulse control, which has manifested as pathological gambling, uncontrolled sexual urges, uncontrolled spending, binge or compulsive eating, and/or other intense urges. Patients with prior history of impulse control issues may be at increased risk. Dose reduction or discontinuation of therapy has been reported to reverse these behaviors in most, but not all, cases (Gaboriau 2014; Moore 2014; Smith 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuroleptic malignant syndrome (NMS): Use may be associated with neuroleptic malignant syndrome (NMS); monitor for mental status changes, fever, muscle rigidity and/or autonomic instability.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Orthostatic hypotension: May cause orthostatic hypotension; use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Temperature regulation: Impaired core body temperature regulation may occur; caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Weight gain: Significant weight gain (&gt;7% of baseline weight) has been observed with antipsychotic therapy; incidence varies with product. Monitor waist circumference and BMI.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiac disease, cerebrovascular disease, prior myocardial infarction, ischemic heart disease, or conditions which predispose to hypotension.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dementia: <b>[US Boxed Warning]: Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death compared to placebo.</b> Most deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Use with caution in patients with Lewy body dementia or Parkinson disease dementia due to greater risk of adverse effects, increased sensitivity to extrapyramidal effects, and association with irreversible cognitive decompensation or death (APA [Reus 2016]). <b>Aripiprazole is not approved for the treatment of dementia-related psychosis.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Parkinson disease: Use with caution in patients with Parkinson disease; antipsychotics may aggravate motor disturbances (APA [Lehman 2004; APA [Reus 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold. Elderly patients may be at increased risk of seizures due to an increased prevalence of predisposing factors.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lactose: Tablets may contain lactose; avoid use in patients with galactose intolerance or glucose-galactose malabsorption.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Phenylalanine: Orally disintegrating tablets may contain phenylalanine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Product interchangeability: Injection: There are two formulations available for intramuscular administration: Abilify is an immediate-release short-acting formulation and Abilify Maintena is an extended-release formulation. These products are <b>not</b> interchangeable.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tablet with sensor: The ability of aripiprazole tablets with sensor to improve patient compliance or modify aripiprazole dosage has not been established. The use of aripiprazole tablets with sensor to track drug ingestion in &ldquo;real time&rdquo; or during an emergency is not recommended because detection may be delayed or not occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of therapy: When discontinuing antipsychotic therapy, the American Psychiatric Association (APA), Canadian Psychiatric Association (CPA), and World Federation of Societies of Biological Psychiatry (WFSBP) guidelines recommend gradually tapering antipsychotics to avoid physical withdrawal symptoms, including anorexia, anxiety, diaphoresis, diarrhea, dizziness, dyskinesia, headache, myalgia, nausea, paresthesia, restlessness, tremulousness and vomiting (APA [Lehman 2004]; CPA [Addington 2005]; Lambert 2007; WFSBP [Hasan 2012]). The risk of withdrawal symptoms is highest following abrupt discontinuation of highly anticholinergic or dopaminergic antipsychotics (Cerovecki 2013). Additional factors such as duration of antipsychotic exposure, the indication for use, medication half-life and risk for relapse should be considered. In schizophrenia, there is no reliable indicator to differentiate the minority who will not from the majority who will relapse with drug discontinuation. However, studies in which the medication of well-stabilized patients were discontinued indicate that 75% of patients relapse within 6 to 24 months. Indefinite maintenance antipsychotic medication is generally recommended, and especially for patients who have had multiple prior episodes or two episodes within 5 years (APA [Lehman 2004]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25819767\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Aripiprazole may cause a higher than normal weight gain in children and adolescents; monitor growth (including weight, height, BMI, and waist circumference) in pediatric patients receiving aripiprazole; compare weight gain to standard growth curves. <b>Note:</b> A prospective, nonrandomized cohort study followed 338 antipsychotic naive pediatric patients (age: 4 to 19 years) for a median of 10.8 weeks (range: 10.5 to 11.2 weeks) and reported the following significant mean increases in weight in kg (and % change from baseline): Olanzapine: 8.5 kg (15.2%), quetiapine: 6.1 kg (10.4%), risperidone: 5.3 kg (10.4%), and aripiprazole: 4.4 kg (8.1%) compared to the control cohort: 0.2 kg (0.65%). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Hyperglycemia has been reported with aripiprazole; in analysis of pediatric trials (patients 6 to 18 years, diagnosis including schizophrenia, autistic disorder, bipolar disorder, and Tourette's disorder), the mean change in fasting glucose was not observed to be significantly different than placebo-treated patients (median exposure range: 43 to 57 days). However, with longer exposure (mean: 17.2 months), an increased risk for the development of type 2 diabetes mellitus (DM) was observed in pediatric patients 10 to 18 years receiving second-generation antipsychotics (SGA); for patients initiated on SGA: 0.4% incidence with mean exposure at time type 2 DM diagnosed: 13.5 months; for SGA noniniators (patients receiving another agent prior to SGA initiation): 0.2% incidence with mean exposure at time of type 2 DM diagnosed: 14.6 months.   Amongst specific SGA&rsquo;s, the risk was highest for aripiprazole (p=0.001) followed by ziprasidone (p=0.06) compared to risperidone as the reference group but not quetiapine or olanzapine (Rubin 2015). Increases in metabolic indices (eg, serum cholesterol, triglycerides) were also reported; however, these changes were not significant in patients receiving aripiprazole (Correll 2009); additionally, in clinical trials, lipid changes observed with aripiprazole monotherapy in pediatric patients were similar to those observed with placebo. Biannual monitoring of cardiometabolic indices after the first 3 months of therapy is suggested (Correll 2009). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Children and adolescents may experience a higher frequency of some adverse effects than adults, including EPS (20% vs 5%), fatigue (17% vs 8%), and somnolence (23% vs 6%). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\"> Pediatric psychiatric disorders are frequently serious mental disorders which present with variable symptoms that do not always match adult diagnostic criteria. Conduct a thorough diagnostic evaluation and carefully consider risks of psychotropic medication before initiation in pediatric patients with schizophrenia, bipolar disorder, or irritability associated with autistic disorder. Medication therapy for pediatric patients with these disorders is indicated as part of a total treatment program that frequently includes educational, psychological, and social interventions. Long-term usefulness of aripiprazole should be periodically re-evaluated in patients receiving the drug for extended periods of time.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP, 1997; Shehab, 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136814\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2D6 (major), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136768\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13180&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amisulpride: Antipsychotic Agents may enhance the adverse/toxic effect of Amisulpride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: Antipsychotic Agents may diminish the stimulatory effect of Amphetamines. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anti-Parkinson Agents (Dopamine Agonist): Antipsychotic Agents (Second Generation [Atypical]) may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).  Management: Consider using an alternative antipsychotic agent when possible in patients with Parkinson disease.  If an atypical antipsychotic is necessary, consider using clozapine or quetiapine, which may convey the lowest interaction risk.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Armodafinil: May decrease the serum concentration of ARIPiprazole.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Moderate): May increase the serum concentration of ARIPiprazole. Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Strong): May increase the serum concentration of ARIPiprazole. Management: See full interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Weak): May increase the serum concentration of ARIPiprazole. Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of ARIPiprazole. Management: Double the oral aripiprazole dose and closely monitor. Reduce oral aripiprazole dose to 10-15 mg/day (for adults) if the inducer is discontinued. Avoid use of strong CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of ARIPiprazole. Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of ARIPiprazole. Management: See full interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Weak): May increase the serum concentration of ARIPiprazole. Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: ARIPiprazole may enhance the adverse/toxic effect of DULoxetine. ARIPiprazole may enhance the serotonergic effect of DULoxetine. This could result in serotonin syndrome. DULoxetine may increase the serum concentration of ARIPiprazole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FLUoxetine: May enhance the adverse/toxic effect of ARIPiprazole. Specifically, the risk of neuroleptic malignant syndrome may be increased. ARIPiprazole may enhance the serotonergic effect of FLUoxetine. This could result in serotonin syndrome. FLUoxetine may increase the serum concentration of ARIPiprazole. Management: Aripiprazole dose should be reduced by at least half, except when used adjunctively for depression. Consult full interaction monograph or aripiprazole prescribing information for complete details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: Antipsychotic Agents may diminish the therapeutic effect of Guanethidine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Haloperidol: ARIPiprazole may enhance the QTc-prolonging effect of Haloperidol. ARIPiprazole may diminish the therapeutic effect of Haloperidol. Haloperidol may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph.  Aripiprazole dose adjustment may not be required when used as adjunctive therapy for major depressive disorder.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: May enhance the neurotoxic effect of Antipsychotic Agents. Lithium may decrease the serum concentration of Antipsychotic Agents. Specifically noted with chlorpromazine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mequitazine: Antipsychotic Agents may enhance the arrhythmogenic effect of Mequitazine.  Management: Consider alternatives to one of these agents when possible.  While this combination is not specifically contraindicated, mequitazine labeling describes this combination as discouraged.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methadone: May enhance the CNS depressant effect of ARIPiprazole. ARIPiprazole may enhance the QTc-prolonging effect of Methadone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: Antipsychotic Agents may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Panobinostat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of sensitive CYP2D6 substrates when possible, particularly those substrates with a narrow therapeutic index.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PARoxetine: May enhance the adverse/toxic effect of ARIPiprazole. Specifically, the risk of neuroleptic malignant syndrome may be increased. ARIPiprazole may enhance the serotonergic effect of PARoxetine. This could result in serotonin syndrome. PARoxetine may increase the serum concentration of ARIPiprazole. Management: Aripiprazole dose adjustment is recommended, except when used adjunctively for depression. Consult full interaction monograph or aripiprazole prescribing information for complete details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perhexiline: CYP2D6 Substrates (High risk with Inhibitors) may increase the serum concentration of Perhexiline. Perhexiline may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: Antipsychotic Agents may diminish the therapeutic effect of Piribedil. Piribedil may diminish the therapeutic effect of Antipsychotic Agents.  Management: Use of piribedil with antiemetic neuroleptics is contraindicated, and use with antipsychotic neuroleptics, except for clozapine, is not recommended.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: Antipsychotic Agents may diminish the therapeutic effect of Quinagolide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: ARIPiprazole may enhance the adverse/toxic effect of Ritonavir. The risk of metabolic disturbances (e.g. hyperglycemia, weight gain, hyperlipidemia) may be increased. Ritonavir may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph.  Aripiprazole dose adjustment may not be required when used as adjunctive therapy for major depressive disorder.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<b> Exceptions: </b>Nicergoline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sertraline: May enhance the adverse/toxic effect of ARIPiprazole. Sertraline may increase the serum concentration of ARIPiprazole. Management: See full interaction monograph.  Aripiprazole dose adjustment may not be required when used as adjunctive therapy for major depressive disorder.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulpiride: Antipsychotic Agents may enhance the adverse/toxic effect of Sulpiride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May increase the serum concentration of ARIPiprazole.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136798\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Ingestion with a high-fat meal delays time to peak plasma level. Management: Administer without regard to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136770\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136784\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Aripiprazole crosses the placenta; aripiprazole and dehydro-aripiprazole can be detected in the cord blood at delivery (Nguyen 2011; Watanabe 2011). Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and/or withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Treatment algorithms have been developed by the ACOG and the APA for the management of depression in women prior to conception and during pregnancy (Yonkers 2009). The ACOG recommends that therapy during pregnancy be individualized; treatment with psychiatric medications during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary health care provider, and pediatrician. Safety data related to atypical antipsychotics during pregnancy is limited, as such, routine use is not recommended. However, if a woman is inadvertently exposed to an atypical antipsychotic while pregnant, continuing therapy may be preferable to switching to an agent that the fetus has not yet been exposed to; consider risk:benefit (ACOG 2008). If treatment is needed in a woman planning a pregnancy or if treatment is initiated during pregnancy, use of an agent other than aripiprazole is preferred (Larsen 2015).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Health care providers are encouraged to enroll women exposed to aripiprazole during pregnancy in the National Pregnancy Registry for Atypical Antipsychotics (866-961-2388 or http://www.womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F999049\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Vital signs; CBC with differential; fasting lipid profile and fasting blood glucose/Hb A<sub>1c</sub> (prior to treatment, at 3 months, then annually); weight, growth, BMI, and waist circumference (especially in children), personal/family history of diabetes, blood pressure, mental status, abnormal involuntary movement scale (AIMS), extrapyramidal symptoms (EPS). Weight should be assessed prior to treatment, at 4 weeks, 8 weeks, 12 weeks, and then at quarterly intervals. Consider titrating to a different antipsychotic agent for a weight gain &ge;5% of the initial weight. Monitor patient periodically for symptom resolution; monitor for worsening depression, suicidality, and associated behaviors (especially at the beginning of therapy or when doses are increased or decreased)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136763\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Aripiprazole is a quinolinone antipsychotic which exhibits high affinity for D<sub>2</sub>, D<sub>3</sub>, 5-HT<sub>1A</sub>, and 5-HT<sub>2A</sub> receptors; moderate affinity for D<sub>4</sub>, 5-HT<sub>2C</sub>, 5-HT<sub>7</sub>, alpha<sub>1</sub> adrenergic, and H<sub>1</sub> receptors. It also possesses moderate affinity for the serotonin reuptake transporter; has no affinity for muscarinic (cholinergic) receptors. Aripiprazole functions as a partial agonist at the D<sub>2</sub> and 5-HT<sub>1A</sub> receptors, and as an antagonist at the 5-HT<sub>2A</sub> receptor (de Bartolomeis 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136780\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note: </b>In pediatric patients 10 to 17 years of age, the pharmacokinetic parameters of aripiprazole and dehydro-aripiprazole have been shown to be similar to adult values when adjusted for weight.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Initial: 1 to 3 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: Extended-release: Slow, prolonged</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Well absorbed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 4.9 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: &ge;99%, primarily to albumin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic dehydrogenation, hydroxylation and N-dealkylation via CYP2D6, CYP3A4 (dehydro-aripiprazole metabolite has affinity for D<sub>2</sub> receptors similar to the parent drug and represents 40% of the parent drug exposure in plasma) (Sheehan 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: IM: 100%; Tablet: 87%; <b>Note: </b>Orally disintegrating tablets are bioequivalent to tablets; oral solution to tablet ratio of geometric mean for peak concentration is 122% and for AUC is 114%.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Aripiprazole: 75 hours; dehydro-aripiprazole: 94 hours; IM, extended release (terminal): ~30 to 47 days (dose-dependent)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CYP2D6 poor metabolizers:  Aripiprazole: 146 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release: 1 to 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release (after multiple doses): 4 days (deltoid administration); 5 to 7 days (gluteal administration)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet: 3 to 5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">With high-fat meal: Aripiprazole: Delayed by 3 hours; dehydro-aripiprazole: Delayed by 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (55%, ~18% of the total dose as unchanged drug; 37% of the total dose as changed drug); urine (25%, &lt;1% of the total dose as unchanged drug; 25% of the total dose as changed drug) (Sheehan 2010)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136783\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Prefilled Syringe</b> (Abilify Maintena Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (1): $1,862.24</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (1): $2,482.99</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (ARIPiprazole Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (150 mL): $1,059.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension Reconstituted ER</b> (Abilify Maintena Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (1): $1,862.24</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (1): $2,482.99</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, orally-disintegrating</b> (ARIPiprazole Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $1,143.86</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (30): $1,143.86</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Abilify Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (30): $1,070.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (30): $1,070.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $1,070.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (30): $1,070.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (30): $1,513.62</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (30): $1,513.62</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (ARIPiprazole Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (30): $963.25</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (30): $963.25</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $963.25</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (30): $963.25</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (30): $1,360.74</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (30): $1,360.74</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539821\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Abdin (PH);</li>\n      <li>Abilify (AE, AT, AU, BB, BE, BG, BH, BR, CH, CL, CN, CO, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HR, HU, ID, IE, IL, IS, IT, JO, JP, KR, KW, LB, LT, LU, MT, MX, MY, NL, NO, PH, PL, PT, PY, QA, RO, RU, SA, SE, SG, SI, SK, TH, TR, TW, VE, VN, ZA);</li>\n      <li>Abilify Discmelt (PH);</li>\n      <li>Abilify Maintena (HK);</li>\n      <li>Abilify OD (JP);</li>\n      <li>Abilify ODT (NZ);</li>\n      <li>Apalife (TH);</li>\n      <li>Arika (TW);</li>\n      <li>Arilental (UA);</li>\n      <li>Arilex (CL);</li>\n      <li>Arinia (BD, ID);</li>\n      <li>Aripi (ID);</li>\n      <li>Aripizole (KR);</li>\n      <li>Ariple (TW);</li>\n      <li>Aripra (KR);</li>\n      <li>Ariprazol (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Ariski (ID);</li>\n      <li>Aristab (BR);</li>\n      <li>Arive (IN);</li>\n      <li>Arixind (AR);</li>\n      <li>Arizol (UY);</li>\n      <li>Arizole (LK, TW);</li>\n      <li>Arlemide (AR);</li>\n      <li>Aryp MT (UA);</li>\n      <li>Azymol (PE, PY);</li>\n      <li>Bisoza (LK, PH);</li>\n      <li>Groven (AR);</li>\n      <li>Ilimit (CR, DO, EC, GT, HN, NI, PA, PE, PY, SV, UY);</li>\n      <li>Irazem (AR);</li>\n      <li>Lemilvo (IE);</li>\n      <li>Mactril (LK);</li>\n      <li>Pipzol (LK, UA);</li>\n      <li>Siblix (AR);</li>\n      <li>Siznil (BD);</li>\n      <li>Sizopra (BD, LK);</li>\n      <li>Viza (CL);</li>\n      <li>Xalipro (LB);</li>\n      <li>Xarip (BD);</li>\n      <li>Zedan (PK);</li>\n      <li>Zipren (ID)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Practice Bulletins-Obstetrics, &quot;ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 92, April 2008 (Replaces Practice Bulletin Number 87, November 2007). Use of Psychiatric Medications During Pregnancy and Lactation,&quot; <i>Obstet Gynecol</i>, 2008, 111(4):1001-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/18378767/pubmed\" target=\"_blank\" id=\"18378767\">18378767</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al, &quot;Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes,&quot; <i>Diabetes Care</i>, 2004, 27(2):596-601.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/14747245/pubmed\" target=\"_blank\" id=\"14747245\">14747245</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bastiaens L, &quot;A Non-Randomized, Open Study With Aripiprazole and Ziprasidone for the Treatment of Aggressive Behavior in Youth in a Community Clinic,&quot; <i>Community Ment Health J</i>, 2009, 45(1):73-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/18597173/pubmed\" target=\"_blank\" id=\"18597173\">18597173</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Budman C, Coffey BJ, Shechter R, et al, &quot;Aripiprazole in Children and Adolescents With Tourette Disorder With and Without Explosive Outbursts,&quot; <i>J Child Adolesc Psychopharmacol</i>, 2008, 18(5):509-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/18928415/pubmed\" target=\"_blank\" id=\"18928415\">18928415</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16529334\"></a>Canadian Psychiatric Association (CPA). Clinical practice guidelines. Treatment of schizophrenia. <i>Can J Psychiatry</i>. 2005;50(13 Suppl 1):7S-57S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/16529334/pubmed\" target=\"_blank\" id=\"16529334\">16529334</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23821039\"></a>Cerovecki A, Musil R, Klimke A, et al. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. <i>CNS Drugs</i>. 2013;27(7):545-572.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/23821039/pubmed\" target=\"_blank\" id=\"23821039\">23821039</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Correll CU, Manu P, Olshanskiy V, et al, &quot;Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents,&quot; <i>JAMA</i>, 2009, 302(16):1765-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/19861668/pubmed\" target=\"_blank\" id=\"19861668\">19861668</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Findling RL, Kauffman R, Sallee FR, et al, &quot;An Open-Label Study of Aripiprazole: Pharmacokinetics, Tolerability, and Effectiveness in Children and Adolescents With Conduct Disorder,&quot; <i>J Child Adolesc Psychopharmacol</i>, 2009, 19(4):431-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/19702495/pubmed\" target=\"_blank\" id=\"19702495\">19702495</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Findling RL, Short EJ, Leskovec T, et al, &quot;Aripiprazole in Children With Attention-Deficit/Hyperactivity Disorder,&quot; <i>J Child Adolesc Psychopharmacol</i>, 2008, 18(4):347-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/18759644/pubmed\" target=\"_blank\" id=\"18759644\">18759644</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22834451\"></a>Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. <i>World J Biol Psychiatry</i>. 2012;13(5):318-378.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/22834451/pubmed\" target=\"_blank\" id=\"22834451\">22834451</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15000267\"></a>Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. <i>Am J Psychiatry</i>. 2004;161(2 Suppl):1-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/15000267/pubmed\" target=\"_blank\" id=\"15000267\">15000267</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lutz UC, Hiemke C, Wiatr G, et al, &ldquo;Aripiprazole in Pregnancy and Lactation: A Case Report,&rdquo; <i>J Clin Psychopharmacol</i>, 2010. 30(2):204-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/20520299/pubmed\" target=\"_blank\" id=\"20520299\">20520299</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marcus RN, Owen R, Kamen L, et al, &quot;A Placebo-Controlled, Fixed-Dose Study of Aripiprazole in Children and Adolescents With Irritability Associated With Autistic Disorder,&quot; <i>J Am Acad Child Adolesc Psychiatry</i>, 2009, 48(11):1110-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/19797985/pubmed\" target=\"_blank\" id=\"19797985\">19797985</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Masi G, Cosenza A, Millepiedi S, et al, &quot;Aripiprazole Monotherapy in Children and Young Adolescents With Pervasive Developmental Disorders: A Retrospective Study,&quot; <i>CNS Drugs</i>, 2009, 23(6):511-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/19480469/pubmed\" target=\"_blank\" id=\"19480469\">19480469</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17195735\"></a>McClellan J, Kowatch R, Findling RL; Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. <i>J Am Acad Child Adolesc Psychiatry</i>. 2007;46(1):107-125.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/17195735/pubmed\" target=\"_blank\" id=\"17195735\">17195735</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mendhekar DN, Sunder KR, and Andrade C, &ldquo;Aripiprazole Use in a Pregnant Schizoaffective Woman,&rdquo; <i>Bipolar Disord</i>, 2006, 8(3):299-300.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/16696834/pubmed\" target=\"_blank\" id=\"16696834\">16696834</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murphy TK, Mutch PJ, Reid JM, et al, &quot;Open Label Aripiprazole in the Treatment of Youth With Tic Disorders,&quot; <i>J Child Adolesc Psychopharmacol</i>, 2009, 19(4):441-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/19702496/pubmed\" target=\"_blank\" id=\"19702496\">19702496</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health. Psychosis and schizophrenia in children and young people: recognition and management. 2013. Available at https://www.nice.org.uk/guidance/cg15526065063</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nguyen T, Teoh S, Hackett LP, et al, &quot;Placental Transfer of Aripiprazole,&quot; <i>Aust N Z J Psychiatry</i>, 2011, 45(6):500-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/21413838 /pubmed\" target=\"_blank\" id=\"21413838 \">21413838 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Owen R, Sikich L, Marcus RN, et al, &quot;Aripiprazole in the Treatment of Irritability in Children and Adolescents With Autistic Disorder,&quot; <i>Pediatrics</i>, 2009, 124(6):1533-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/19948625/pubmed\" target=\"_blank\" id=\"19948625\">19948625</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15949658\"></a>Remington G, Chue P, Stip E, Kopala L, Girard T, Christensen B. The crossover approach to switching antipsychotics: what is the evidence? <i>Schizophr Res</i>. 2005;76(2-3):267-272.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/15949658/pubmed\" target=\"_blank\" id=\"15949658\">15949658</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubin DM, Kreider AR, Matone M, et al. Risk for incident diabetes mellitus following initiation of second-generation antipsychotics among Medicaid-enrolled youths. <i>JAMA Pediatr</i>. 2015;169(4):e150285.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/25844991/pubmed\" target=\"_blank\" id=\"25844991\">25844991</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schlotterbeck P, Leube D, Kircher T, et al, &ldquo;Aripiprazole in Human Milk,&rdquo; <i>Int J Neuropsychopharmacol</i>, 2007, 10(3):433.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/17291382/pubmed\" target=\"_blank\" id=\"17291382\">17291382</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Seo WS, Sung HM, Sea HS, et al, &quot;Aripiprazole Treatment of Children and Adolescents With Tourette Disorder or Chronic Tic Disorder,&quot; <i>J Child Adolesc Psychopharmacol</i>, 2008, 18(2):197-205.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/18439116 /pubmed\" target=\"_blank\" id=\"18439116 \">18439116 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stigler KA, Diener JT, Kohn AE, et al, &quot;Aripiprazole in Pervasive Developmental Disorder Not Otherwise Specified and Asperger's Disorder: A 14-Week, Prospective, Open-Label Study,&quot; <i>J Child Adolesc Psychopharmacol</i>, 2009, 19(3):265-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/19519261/pubmed\" target=\"_blank\" id=\"19519261\">19519261</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Valicenti-McDermott MR and Demb H, &quot;Clinical Effects and Adverse Reactions of Off-Label Use of Aripiprazole in Children and Adolescents With Developmental Disabilities,&quot; <i>J Child Adolesc Psychopharmacol</i>, 2006, 16(5):549-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/17069544 /pubmed\" target=\"_blank\" id=\"17069544 \">17069544 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Watanabe N, Kasahara M, Sugibayashi R, et al, &quot;Perinatal Use of Aripiprazole: A Case Report,&quot; <i>J Clin Psychopharmacol</i>, 2011, 31(3):377-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/21532364/pubmed\" target=\"_blank\" id=\"21532364\">21532364</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yonkers KA, Wisner KL, Stewart DE, et al, &quot;The Management of Depression During Pregnancy: A Report From the American Psychiatric Association and the American College of Obstetricians and Gynecologists,&quot; <i>Obstet Gynecol</i>, 2009, 114(3):703-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/19701065/pubmed\" target=\"_blank\" id=\"19701065\">19701065</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yoo HK, Choi SH, Park S, et al, &quot;An Open-Label Study of the Efficacy and Tolerability of Aripiprazole for Children and Adolescents With Tic Disorders,&quot; <i>J Clin Psychiatry</i>, 2007, 68(7):1088-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/17685747/pubmed\" target=\"_blank\" id=\"17685747\">17685747</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yoo HK, Lee JS, Paik KW, et al, &quot;Open-Label Study Comparing the Efficacy and Tolerability of Aripiprazole and Haloperidol in the Treatment of Pediatric Tic Disorders,&quot; <i>Eur Child Adolesc Psychiatry</i>, 2011, 20(3):127-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-pediatric-drug-information/abstract-text/21188439/pubmed\" target=\"_blank\" id=\"21188439\">21188439</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13180 Version 235.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50629640\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708627\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F136801\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F9490633\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F999002\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F999039\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F136774\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F136761\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F26641004\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F49685671\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874282\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F999047\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F136797\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F999003\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F136828\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F136826\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F136781\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F136764\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25819767\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F136814\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F136768\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F136798\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F136770\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F136784\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F999049\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F136763\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F136780\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F136783\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539821\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13180|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-drug-information\" class=\"drug drug_general\">Aripiprazole (short-acting oral and injectable; and long-acting injectable [Abilify Maintena]): Drug information</a></li><li><a href=\"topic.htm?path=aripiprazole-short-acting-oral-and-injectable-and-long-acting-injectable-abilify-maintena-patient-drug-information\" class=\"drug drug_patient\">Aripiprazole (short-acting oral and injectable; and long-acting injectable [Abilify Maintena]): Patient drug information</a></li></ul></div></div>","javascript":null}